A Phase 4 interventional study of Pericapsular nerve group (PENG) block and Bupivacaine in Pain, Postoperative, Muscle Weakness and Arthroplasty, Replacement, Hip, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Open to participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Ain Shams University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 149 studies testing dexamethasone in Pain, Postoperative — 27 open to participants now, 31 under way, 2 of them phase 3. Dexamethasone · Pain, Postoperative.
Among the 149 studies testing dexamethasone in Pain, Postoperative, this one is the 99th largest by planned enrollment, is one of 17 that started in 2026, is one of 75 in phase 4, reaches primary completion later than 26 of the 30 other live ones, and was the 147th registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →27 of the 149 studies testing dexamethasone in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19–79
Marmara University · Sites in Turkey
Ages 18–65 · Healthy volunteers
Beijing Tiantan Hospital · Sites in China
Ages 18–65
Oman Ministry of Health · Sites in Oman
Ages 21–80
University of Saskatchewan · Sites in Canada
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 50 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
149 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 14 · Phase 3 19 · Phase 4 75
First in 2005; this study’s year is marked. 17 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 88 across the 149 interventional studies. Of the 96 that completed or were terminated, 22 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 149 have an industry lead sponsor. The 10 most frequent:
Ain Shams University is the lead sponsor of 1,958 studies on the registry; 432 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
102 studies in Pain, Postoperative by Ain Shams University: 24 open now, 28 under way, 2 of them phase 3. Of 63 finished, 3 (5%) have results posted.
Among the 102 studies in Pain, Postoperative by Ain Shams University, this one is the 46th largest by planned enrollment of the 100 interventional ones that give a count, is one of 9 that started in 2026, is one of 14 in phase 4, reaches primary completion later than 24 of the 27 other live ones, and was the 101st registered.
Ain Shams University’s Pain, Postoperative studies by the year they started, since 2013.
11 of the studies testing dexamethasone in Pain, Postoperative that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07847047Phase 3Assiut UniversitySafety and Efficacy of Dexamethasone Versus Dexmedetomidine as Adjuvants in PENG Block in Hip Surgeries for Postoperative Pain Management | 2027-10 |
| NCT07795281Gaziantep City HospitalIntravenous Dexamethasone Added to Dexmedetomidine After Superior Trunk Block | 2026-12 |
| NCT07380139Ain Shams UniversityDexamethasone vs Dexmedetomidine in Sphenopalatine Ganglion Block for Rhinoplasty Pain | 2026-12-01 |
| NCT07672873Marmara UniversityLocal Dexamethasone Administration in Symptomatic Irreversible Pulpitis | 2026-12-15 |
| NCT07099222University of ArizonaEfficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 149 studies testing dexamethasone in Pain, Postoperative, from their registry updates:
Among Ain Shams University’s 102 in Pain, Postoperative:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to compare two regimens of the pericapsular nerve group (PENG) block, an ultrasound-guided injection of local anaesthetic targeting the nerves supplying the front of the hip joint, for postoperative pain relief and quadriceps muscle function in patients undergoing primary unilateral total hip arthroplasty under spinal anaesthesia.
The PENG block was originally proposed as a motor-sparing technique. However, the standard 20 mL volume can spread to the femoral nerve and cause quadriceps weakness. Reducing the injected volume may limit this spread and better preserve quadriceps strength, but smaller volumes risk shorter analgesic duration. Adding dexamethasone to a low-volume injection may compensate for the reduced volume.
The main questions this trial aims to answer are:
Researchers will compare:
Participants will:
The primary outcome is the time from completion of the PENG block to the first administration of rescue analgesia, recorded over the first 24 hours postoperatively. The study will be conducted at Ain Shams University Hospitals (El Demerdash Hospital) and will include 60 patients (30 per group), aged 50 to 70 years, ASA physical status I or II.
Background: Hip surgery is associated with moderate to severe postoperative pain that, if poorly controlled, delays mobilization, prolongs hospital stay, and increases complications in a frequently elderly population. Opioid-based analgesia is limited by dose-dependent adverse effects such as sedation, respiratory depression, nausea, vomiting, and constipation, particularly harmful in older patients. Peripheral nerve blocks provide effective analgesia, reduce opioid requirements, and are therefore central to enhanced recovery pathways after hip surgery.
The anterior hip capsule, the most densely innervated region of the joint, receives sensory articular branches from the femoral, obturator, and accessory obturator nerves. These arise cephalad to the inguinal ligament and are therefore not reliably captured by traditional infra-inguinal techniques such as the femoral nerve block or fascia iliaca compartment block.
The pericapsular nerve group (PENG) block was described in 2018 as an ultrasound-guided injection of local anaesthetic into the musculofascial plane between the psoas tendon and the iliopubic eminence, targeting these articular branches while theoretically sparing motor components. Meta-analyses of randomized trials confirm that the PENG block reduces postoperative opioid consumption and pain scores after hip surgery and facilitates positioning for neuraxial anaesthesia.
Despite being promoted as motor-sparing, the PENG block performed with the conventional 20 mL volume has been repeatedly associated with quadriceps weakness, reported in approximately 25% or more of patients, attributed to spread of local anaesthetic toward the femoral nerve proper within the fascia iliaca compartment. Cadaveric and imaging studies support a volume-dependent relationship: larger volumes increase femoral nerve staining, whereas smaller volumes reduce this risk. A cadaveric study estimated the maximum effective volume sparing the femoral nerve in 90% of specimens to be approximately 13.2 mL.
However, lowering the volume may shorten the duration of analgesia. Dexamethasone is among the most studied adjuvants for peripheral nerve blocks and can prolong analgesia of long-acting local anaesthetics while reducing postoperative nausea and vomiting; the analgesic benefit is largely achieved at a dose of approximately 4 mg.
A preliminary randomized trial reported that adding dexamethasone to ropivacaine for the PENG block prolonged postoperative analgesia compared with ropivacaine alone. The PENG block has also been shown to improve early functional recovery and reduce time to ambulation after hip arthroplasty. More recent work suggests that combining dexamethasone with a reduced local anaesthetic volume in PENG block can maintain analgesia while preserving quadriceps strength. However, the available evidence largely employs ropivacaine and time-to-first rescue as the principal endpoint; data on a bupivacaine-based low-volume regimen with dexamethasone, evaluated as a complete analgesic strategy, remain limited, which forms the rationale for the present study.
Aim: To compare the analgesic efficacy and quadriceps motor function of two PENG block regimens, a low-volume block (10 mL bupivacaine 0.25%) with 4 mg dexamethasone versus a standard-volume block (20 mL bupivacaine 0.25%), in patients undergoing primary unilateral total hip arthroplasty.
Study design and setting: Prospective, randomized, controlled clinical trial conducted at Ain Shams University Hospitals (El Demerdash Hospital). Study period: 1 year.
Randomization and blinding: Eligible patients who fulfil the inclusion criteria and consent to participate will be randomly allocated into two equal groups using computer-generated random numbers, such that patients with even numbers will be enrolled in Group A (standard-volume PENG block) and patients with odd numbers will be enrolled in Group B (low-volume PENG block with dexamethasone). The participants, the outcome assessors and the data analyst will be blinded to group allocation.
Study procedure:
Primary outcome: Time to first rescue analgesia, defined as the interval (in hours) from completion of the PENG block to the first administration of rescue analgesia (NRS 4 or more), recorded over the first 24 hours postoperatively.
Secondary outcomes:
Sample size: Using the Power Analysis and Sample Size (PASS) 11 program, results from a previous randomized trial showed that the PENG plus dexamethasone group demonstrated a significantly longer time to first rescue opioid analgesia (15.0 +/- 1.5 hours vs 9.1 +/- 1.7 hours). Based on these findings, a sample size of 30 patients per group achieves 100% power to reject the null hypothesis of equal means when the population mean difference is 5.9 hours with standard deviations of 1.5 for group 1 and 1.7 for group 2, and with a significance level (alpha) of 0.05 using a two-sided two-sample unequal-variance t-test.
Statistical analysis: Data will be coded and analyzed using the Statistical Package for the Social Sciences (SPSS) version 23. The primary outcome (time to first rescue analgesia) will be analyzed using Kaplan-Meier survival analysis with the log-rank test, and a Cox proportional-hazards model will be used to estimate the hazard ratio with 95% confidence interval. Quantitative parametric data will be presented as mean +/- standard deviation (SD) and compared using the unpaired Student t-test; non-parametric data as median (interquartile range, IQR) using the Mann-Whitney test; and qualitative data as number and percentage using the chi-square or Fisher exact test. Repeated measurements over time (NRS, MRC) will be analyzed using a linear mixed-effects model. Analyses will follow both the intention-to-treat and per-protocol principles, with block failure and conversion to general anaesthesia handled as protocol deviations and reported. A p-value \< 0.05 will be considered statistically significant.
Ethical considerations: The study will be conducted after approval from the Research Ethics Committee, Faculty of Medicine, Ain Shams University, and will be prospectively registered before enrolment of the first participant. Informed written consent will be obtained from all patients after a detailed explanation of the study procedure, including the off-label use of dexamethasone, the potential risks of the block (nerve injury, infection, local anaesthetic systemic toxicity), and the right to withdraw at any time without affecting their care. The privacy of participants and confidentiality of data will be guaranteed throughout all phases of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive an ultrasound-guided PENG block with 5 mL of bupivacaine 0.5% (25 mg) plus 4 mL of normal saline plus 4 mg dexamethasone in 1 mL, giving a total injectate volume of 10 mL of bupivacaine 0.25%, after spinal anaesthesia.
Procedure: Pericapsular nerve group (PENG) block · Drug: Bupivacaine · Drug: Dexamethasone
Patients will receive an ultrasound-guided PENG block with 20 mL of bupivacaine 0.25% (50 mg) after spinal anaesthesia.
Procedure: Pericapsular nerve group (PENG) block · Drug: Bupivacaine
An 80-100 mm, 22-gauge echogenic needle is advanced in-plane from lateral to medial into the plane between the psoas tendon and the iliopubic eminence under ultrasound guidance using a low-frequency curvilinear transducer (2-5 MHz), and the local anaesthetic is injected in increments after negative aspiration. Correct injectate spread deep to the psoas tendon will be confirmed sonographically.
Also known as: PENG block
Group A: 20 mL of bupivacaine 0.25% (50 mg). Group B: 5 mL of bupivacaine 0.5% (25 mg) diluted to a total injectate volume of 10 mL of bupivacaine 0.25%. Injected as the PENG block.
Also known as: Marcaine
4 mg dexamethasone in 1 mL added to the PENG block injectate in Group B (perineural).
Also known as: Decadron
Time to First Rescue Analgesia
The interval (in hours) from completion of the PENG block to the first administration of rescue analgesia (intravenous nalbuphine 5 mg, given when the Numerical Rating Scale pain score is 4 or more on a 0-10 scale, where 0 = no pain and 10 = worst possible pain).
Time frame: From completion of the PENG block up to 24 hours postoperatively
Incidence and Severity of Quadriceps Weakness
Quadriceps strength on the operated side assessed using the Medical Research Council (MRC) scale (0-5, where 0 = no contraction and 5 = normal power) together with the ability to perform a straight leg raise, compared with the preoperative baseline. Clinically significant weakness is defined as a reduction of one or more MRC grades or inability to perform a straight leg raise.
Time frame: Preoperative baseline and at 6, 12 and 24 hours postoperatively
Total Opioid Consumption
Total dose (mg) of rescue intravenous nalbuphine administered over the first 24 hours postoperatively.
Time frame: First 24 hours postoperatively
Time to First Ambulation
Time (in hours) to first ambulation.
Time frame: Within the first 24 hours postoperatively
Plan to share: Yes — De-identified individual participant data underlying the published results will be made available upon reasonable request to the principal investigator.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Beginning 6 months after publication of the primary results, for a period of 3 years.
Access criteria: Requests from qualified researchers with a methodologically sound proposal, subject to approval by the principal investigator and the Research Ethics Committee, Faculty of Medicine, Ain Shams University, and a signed data access agreement.
Started Oct 2026 (actual). Primary completion is estimated for Aug 2027, 10 months after the start.
Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 10 months is below that.
Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone